Mechanism of cleavage of alpha-synuclein by the 20S proteasome and modulation of its degradation by the RedOx state of the N-terminal methionines  by Alvarez-Castelao, Beatriz et al.
Biochimica et Biophysica Acta 1843 (2014) 352–365
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrMechanism of cleavage of alpha-synuclein by the 20S proteasome and
modulation of its degradation by the RedOx state of the
N-terminal methioninesBeatriz Alvarez-Castelao a, Marc Goethals b,c, Joël Vandekerckhove b,c, José G. Castaño a,b,⁎
a Departamento de Bioquímica, Instituto de Investigaciones Biomédicas “Alberto Sols”, UAM-CSIC y Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
(CIBERNED), Spain
b Department of Biochemistry, Ghent University, Ghent, Belgium
c Department of Medical Protein Research, VIB, Ghent Univeristy, Ghent, Belgium⁎ Corresponding author at: Departamento de Bioquími
Biomédicas “Alberto Sols”, UAM-CSIC, Facultad de Medici
de Madrid, 28029 Madrid, Spain. Fax: +34 91 585 4401.
E-mail address: joseg.castano@uam.es (J.G. Castaño).
0167-4889/$ – see front matter © 2013 Elsevier B.V. All r
http://dx.doi.org/10.1016/j.bbamcr.2013.11.018a b s t r a c ta r t i c l e i n f oArticle history:
Received 25 May 2013
Received in revised form 29 October 2013
Accepted 24 November 2013
Available online 3 December 2013
Keywords:
Protein degradation
Alpha-synuclein
Proteasome
RedOx
MsrA and B
Parkinson's diseaseAlpha-synuclein is a small protein implicated in the pathophysiology of Parkinson's disease (PD). We have
investigated the mechanism of cleavage of alpha-synuclein by the 20S proteasome. Alpha-synuclein interacts
with the C8 (α7) subunit of the proteasome. The N-terminal part of alpha-synuclein (amino acids 1–60) is
essential for its proteasomal degradation and analysis of peptides released from proteasomal digestion allows
concluding that initial cleavages occur within the N-terminal region of the molecule. Aggregated alpha-
synucleins are also degraded by the proteasome with a reduced rate, likely due to Met oxidation. In fact, mild
oxidation of alpha-synuclein with H2O2 resulted in the inhibition of its degradation by the proteasome, mainly
due to oxidation of Met 1 and 5 of alpha-synuclein. The inhibition was reversed by treatment of the oxidized
protein with methionine sulfoxide reductases (MsrA plus MsrB). Similarly, treatment with H2O2 of N2A cells
transfected with alpha-synuclein resulted in the inhibition of its degradation that was also reverted by
co-transfection of MsrA plus MsrB. These results clearly indicate that oxidative stress, a common feature of PD
and other synucleinopathies, promotes a RedOx change in the proteostasis of alpha-synuclein due to Met
oxidation and reduced proteasomal degradation; compromised reversion of those oxidative changes would
result in the accumulation of oxidative damaged alpha-synuclein likely contributing to the pathogenesis of PD.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Idiopathic Parkinson's disease (PD), dementia with Lewy bodies
and multiple system atrophy are characterized pathologically by
proteinaceous inclusions commonly described as Lewy pathology in
postmortem brain tissue samples [21]. Alpha-synuclein (Snca) is the
major protein constituent of Lewy bodies [49]. Three missense point
mutations (Ala53Thr, Ala30Pro, Glu46Lys) in the SNCA gene have
been linked to dominant early-onset familial PD [42,28,63]. SNCA
locus duplication [11,25], and also triplication [48] have been described
in certain forms of familial PD. Furthermore, hypomethylation of SNCA
intron 1 is found in sporadic PD patients [26], indicating that increased
expression of Snca is also directly involved in the pathogenesis of PD
and neurodegeneration.
Snca is a small acidic protein of 140 amino acids. The N-terminal
region of Snca contains 7 imperfect repeats with the consensus coreca e Instituto de Investigaciones
na de la Universidad Autónoma
ights reserved.sequence Lys-Thr-Lys-Glu-Gly-Val, then it is followed by a central
hydrophobic region which includes the non-amyloid component
found in Alzheimer's amyloid plaques [53] and ﬁnally a C-terminal
portion that has no recognized structural elements except for a strong
negative charge. The precise function of Snca is not clear. Snca has
been characterized from the time of its initial isolation as a native
unfolded protein [61,13], a fact further strengthened by recent studies
[17,9] promoted by the publication of some reports indicating that
native Snca could be a tetramer [6,57]. Snca is able to undergo self-
aggregation in a nucleation-dependent process to form non-ﬁbrillar
oligomers, protoﬁbrils and ﬁbrillar aggregates with amyloid-like
properties that are potentially cytotoxic [14]. Snca has been shown to
be directly degraded in vitro by the 20S proteasome [51,30,35,1]. Snca
degradation in cell culture experiments has been shown to bemediated
by the proteasome [7,60] togetherwith the autophagic pathway [60,16].
In this study we have analyzed the mechanism of degradation
of Snca by the 20S proteasome. Experimental evidence is provided
that the degradation could be explained by the interaction of C8
(α7) proteasomal subunit through its C-terminal region with the
N-terminal region of Snca (1–60). A detailed peptide analysis of the
products released by proteasomal digestion of native Snca is also
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suspect that oxidation of Met may play a role in Snca degradation
by the proteasome. Following that hint, we present here direct
experimental evidence that N-terminal Met oxidation of native Snca
inhibits its degradation by the proteasome, and that it can be reversed
by repair of oxidized Snca with methionine sulfoxide reductases, both
in vitro and in transfected cells.
2. Materials and methods
2.1. Plasmid constructs
Human wild type Snca cDNA was obtained by PCR with the
appropriate oligonucleotides from a human placental cDNA library
and cloned into NdeI/SalI sites of pT7-7 vector. pT7-7 Snca A30P,
A53T, and E46K were obtained by PCR with QuikChange™ Site-
Directed Mutagenesis Kit from Stratagene. Snca stop 109 was obtained
by PCR using the following oligonucleotides; forward; 5′AGAAGGAG
CCCCACAGTAAGGAATTCTGGAAGATATGC 3′, reverse; 5′GCATATCTTC
CAGAATTCCTTACTGTGGGGCTCCTTCT 3′. His-tagged Snca (His-Snca,
His-Snca 1–60, His-Snca 1–95, His-Snca 61–140), were obtained by
PCR with the appropriate oligonucleotides (forward BglII-Snca; 5′
GGCGGCGAGATCTATGGATGTATTCATGAAAGG 3′, forward BglII-Snca
61–140; 5′GGCCACATCTATGGAGCAAGTGACAAATGTTGGAGG 3′, re-
verse SalI-Snca; 5′AGAGTCGACTTAGGCTTCAGGTTCG 3′, reverse SalI-
Snca 1–60; 5′GGGCCGTCGACCTATTTGGTCTTCTCAGCCACT 3′, reverse
SalI-Snca 1–95; 5′GGGCCGTCGACTTAGACAAAGCCAGTGGCTGC 3′) and
cloned into the pRSET-A vector by digestion with BamHI/XhoI. Snca
M5A was obtained by PCR with; forward NdeI-Snca M5A; 5′GCAGGA
TCCATATGGATGTATTTCGCGAAAGGACTTTCAAAGG 3′, and reverse
SalI-Snca oligonucleotide (described above) and cloned into pT7-7 vec-
tor as described previously. His-tag Snca M1,5A was obtained by PCR
from pET15B Snca (inserted into NdeI/XhoI sites) with QuikChange™
Site-Directed Mutagenesis Kit from Stratagene with; forward Snca
M1,5A; 5′GCCGCGCGGCAGCCATGCGGATGTATTCGCGAAAGGACTTTC
AAAGG 3′, and reverse 3′Snca M1,5A; 5′CCTTTGAAAGTCCCTTCGCGAA
TACATCCCGCATGGCTGCCGCGCGGC 3′, this construct was used as
template for PCR ampliﬁcation with forward Snca M1,5A and reverse
SalI-Snca oligonucleotides, the PCR product was treated with T4
polynucleotide kinase (Promega), according to the manufacturer's
instructions, and directly subcloned into PvuII blunt site of pRSET-A
vector.
Human methionine sulfoxide reductase A (hMsrA) cDNA was
obtained from I.M.A.G.E. consortium (IMAGE: 6504055. MGC: 64957)
and subcloned by PCR with the following oligonucleotides; forward
BamHI-NdeI-hMsrA; 5′-CGCAGGATCCCATATGTGCTCTGAGCCCAAACAC
CATGTCAACGG-3′, and reverse XhoI-hMsrA; 5′-GCCTCGAGTTACTTCT
TAATACCCACTGGGCAG-3′ into pGEX4T-1 vector after digestion with
BamHI/XhoI and also into pcDNA 3.1 (+) Zeo vector. hMsrB2
(BC130380, MGC:163252, IMAGE:40146411) was cloned into pRSETB
with the following oligonucleotides: forward BglII; 5′CCGAGATCTATG
GCGCGGCTCCTCTGG3′ Reverse EcoRI 5′AGCGAATTCCTTGTGACGTAGA
ACTGCTCC3′ digested with the corresponding enzymes and ligated
into the BglII/EcoRI sites of pRSETB, and in the BamHI/EcoRI sites of
pcDNA 3.1(+) Zeo vector.
Recombinant full length C2 (α6), C8 (α7) and C9 (α3) constructs
have been described previously [3]. GST-C8 C-terminal construct was
obtained by subcloning the EcoRV-Sal1 (a.a. 190 to 255) fragment
from pT7-7 HC8 into pGEX vector (Sma1/Sal1). All constructs were
fully sequenced by the chain termination method.
2.2. Protein puriﬁcation
Rat liver 20S proteasome was puriﬁed as described [4]. Snca wild
type, A30P, A53T and E46K were produced and puriﬁed essentially as
described [32]. Recombinant proteasomal subunits, C2 (α6), C8 (α7)and C9 (α3), and GST-C8 C-terminus were puriﬁed as described
[3,10]. Recombinant GST constructs (GST, GST-Snca WT, GST-Snca
1–60, GST-Snca 1–95, GST-Snca 61–140, GST-hMsrA and GST-TRP32)
were obtained from induced bacterial cultures and puriﬁed using
glutathione-Sepharose (GE Healthcare), according to the manufac-
turer's instructions. hMsrB2 was obtained from induced bacterial
cultures and puriﬁed using Ni-NTA agarose (Qiagen), according to the
manufacturer's instructions, and digested with Enterokinase (Sigma)
for His-tag excision as per manufacturer protocols.
Recombinant His tag protein constructs (His-Snca WT, His-Snca
M5A; M1,5A, His-Snca 1–60, His-Snca 1–95 and His-Snca 61–140)
were puriﬁed using Ni-NTA agarose (Qiagen), according to the
manufacturer's instructions. All proteins were dialyzed against a buffer
containing 25 mM Tris–Cl pH 7.5; insoluble proteins were removed
by centrifugation at 100,000 ×g for 30 min and stored frozen at −
70 °C until used. His-tagged Snca wild type and Snca M5A and M1, 5A
mutants were treated with enterokynase (New England Biolabs)
or Thrombin CleanCleave kit (Sigma), for His-tag removal as per
manufacturer protocols.
2.3. Snca biotinylation and “Far-Western” analysis
Snca was biotinylated by incubation with 12-fold molar excess of
NHS–biotin for 2 h at 37 °C in 10 mMHepes–NaOH pH 7.4, and excess
biotin was quenched with 0.5 M Tris–glycine as described by the
manufacturer (Pierce). Biotinylated Snca was dialyzed overnight
against H2O and stored frozen at−70 °C. Degradation of biotinylated
Snca was performed as described below, and after SDS-PAGE, the gels
were transferred to nitrocellulose. Blots were blocked for 3 h with
blocking buffer (T-TBS: 50 mM Tris–Cl pH 7.5, 0.15 M NaCl; containing
0.1% Tween-20 and 3% BSA) and incubated for 30 min with 0.25 μg/ml
alkaline-phosphatase conjugated streptavidin in blocking buffer.
The blots were washed 3 times (10 min each) with T-TBS, once with
TBS, and then developed with 5-Bromo-4-Chloro-3′-Indolyphosphate
p-toluidine (BCIP) and Nitro-Blue Tetrazolium chloride (NBT). To
study the binding of Snca to the puriﬁed proteasome complex or
recombinant proteins, the different proteins to be analyzed were
separated by 12% SDS-PAGE and transferred to nitrocellulose. Blots
were washed 5–6 times (10 min each at room temperature) with
50 mM Tris–HCl pH 7.5, 50 mM NaCl, 0.1% Tween and 0.1% BSA and
blocked overnight at 4 °C in the same buffer. Next day, blots were
incubated for 3 h at room temperature in the same buffer as above,
but containing 1 μg/ml of biotinylated Snca. Filter membranes were
washed 3 times (10 min each) with the same buffer, incubated for
30 min with 0.25 μg/ml alkaline-phosphatase conjugated streptavidin
in the same buffer, washed again for three times as above, and
developed with BCIP and NBT. All these procedures were also
performed at room temperature.
2.4. In vitro Snca aggregation
For aggregation studies, the different puriﬁed Snca proteins were
ﬁltered sterilized (0.2 μm) and incubated at a minimal concentration
of 1 mg/ml in PBS, in the presence of 0.01% NaN3 at 37 °C with constant
shaking for different periods from 1 day to 1 month, where indicated;
10 mM 2-mercaptoethanol was added to prevent protein oxidation.
The Met 1, 5 Ala mutant was aggregated under similar conditions
described above for wild type Snca. The degree of aggregation
was quantitated by mixing aliquots of aggregated Snca with 10 μM
Thioﬂavin T (Sigma) in 10 mM Tris–Cl pH 8.0. Fluorescence was
measured in whole black 96-well plates with a microplate ﬂuorescence
reader Inﬁnite M1000 (Tecan) using Ex/Em 450/480 nm wavelengths.
Aggregated Sncas were also analyzed by SDS-PAGE followed by
silver staining [36] or by Western immunoblotting with anti-Snca
monoclonal antibody (Syn-1, BD), or our in-house produced
polyclonal anti-Snca antibody. An aliquot of the aggregated Snca
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negatively stained with 1% uranyl acetate and observed by electron
microscopy (JEOL-1200EX).
2.5. In vitro degradation assay
Degradation reactions contained in a ﬁnal volume of 20 μl: 20 mM
Hepes–NaOH pH 7.4, 2 mM EDTA, 1 mM EGTA, 3.5–7 μM of the puri-
ﬁed recombinant Snca and 69–173 nM puriﬁed rat liver proteasome,
or as indicated. Reactions were incubated at 37 °C for the indicated
times and stopped with concentrated SDS-PAGE sample buffer. Control
reactions contained 10 μM Lactacystin (proteasome inhibitor), or no
proteasome (control for endogenous degradation). After boiling for
5 min samples were loaded onto 12–14% SDS-PAGE. Gels were stained
(Coomasie blue or silver staining), destained and dried under vacuum,
or analyzed by Western immunoblotting, with Snca monoclonal
antibody or in-house produced anti-GST and Snca rabbit polyclonal
antibodies. Quantitation was performed using the Quantity-one
software (BioRad).
2.6. Pull-down assays
GST or GST-C8Ct bound to glutathione-Sepharose beads (amount of
beads equivalent to approximately 1 μg of each recombinant protein)
were blocked by washing the beads three times with blocking buffer;
50 mM Tris–Cl pH 7.5, 50 mM NaCl, 0.1% Tween and 0.1% BSA
and ﬁnally three times with the same buffer but without BSA. Snca
(2 μg) was added to the beads in 50 mM Tris–HCl pH 7.5, 50 mM
NaCl, 0.1% Tween and incubated for 2 h at room temperature. After
incubation, beads were washed three times with the above
buffer (without BSA), and resuspended in SDS-PAGE loading buffer
for loading onto 14% SDS-PAGE. Gels were stained with Coomassie
Brilliant Blue.
2.7. Peptide analysis by mass spectrometry
Degradation reaction mixtures were stopped with 10 volumes of
0.1% TFA and subjected to reverse-phase HPLC on a 4.6 × 250-mm
Vydac C18 column (Vydac, Hesperia, CA) in 0.1% TFA with a ﬂow rate
of 1 ml/min and resolved with a linear gradient 0–30% acetonitrile in
0.1% TFA. Eluted fractions were manually collected and dried in a
Speed-Vac (Savant). Peptide analysis was performed by Edman
degradation (477A Applied Biosystems) for direct N-terminus
sequencing and by MALDI/TOF MS/MS [19], or alternatively by
electrospray ionization mass spectrometry (ESI-MS) using a
nanoelectrospray ionization source and MS/MS. In the latter case,
spectra were acquired in a data-dependent mode on an ion-trap mass
spectrometer (Esquire HCT, Bruker). ESI-MS was also used to study
native molecular weight of Snca.
2.8. In vitro oxidation and hMsrA and B repair assay of oxidized Snca
Recombinant human Snca was oxidized by three different methods:
H202, chloramine T, and FeCl3 plus ascorbic acid. For oxidation with
H2O2; 40 μM Snca was incubated with 0.5% H2O2 and 10 mM Hepes–
NaOH pH 7.4, for 3 h at 30 °C with shaking, reactions were stopped
with 10 mM DTT. Oxidation with chloramine T (ChT); 40 μM Snca
was incubated with 1 mM chloramine T and 10 mM Hepes–NaOH
pH 7.4 for 1 h at 37 °C. Oxidized proteinswere dialyzed inMini Dialysis
Units (Pierce) overnight with 104 times sample volume of ddH2O,
changing water two times. Oxidation with FeCl3 plus ascorbic acid;
40 μM Snca was incubated with 0.1 mM FeCl3, 25 mM ascorbic acid,
100 mM KCl and 10 mM MgCl2, for 3 h at 37 °C. Reactions were
stopped with 1 mM EDTA, dialyzed twice for 1 h against 1 mM EDTA,
and further dialyzed overnight with ddH2O changing water two times.
Carbonylated Snca was analyzed by Western immunoblotting afterderivatization using the Oxyblot kit (Oxyblot Detection, Chemicon
International Inc.). Freshly puriﬁed recombinant human GST-MsrA
was bound to glutathione-Sepharose beads. Nonspeciﬁc binding
was prevented by incubation of the beads with blocking buffer
(see Pull-down assays), and then incubated together with his-tag
excised hMsrB and native or oxidized Snca in a buffer containing
50 mM Tris–Cl pH 7.5, 50 mM NaCl, with or without 4 mM DTT,
8 h at 37 °C. Control reactions contained native Snca or oxidized
Snca and were incubated under the same conditions with
blocked GST-glutathione-Sepharose beads and no methionine
sulforeductases.2.9. Cellular studies
N2A cells were grown in Dulbecco Modiﬁed Eagle's medium
containing 10% of fetal bovine serum. Cells were transiently transfected
with Snca cDNA [1] plus empty vector or plus pcDNA MsrA and B
constructs using Lipofectamine reagent (Invitrogen). Cells, 48 h after
transfection, were washed three times with PBS and either not treated
or treated with a bolus of 0.4 mM H2O2, for 30 min at 37 °C in PBS.
After treatment, cells were washed with complete medium and further
cultured in the presence of 20 μg/ml of cycloheximide (CHX) for the
times indicated in the absence or in the presence of 10 μM lactacystin.
The treatment with 0.4 mM H2O2 was repeated every 24 h to keep
the cells under oxidative stress. Cell viability by Trypan blue exclusion
was ≥90%. Cells were collected at the times indicated and processed
for immunoblot analysis, as described previously [1]; we used antibod-
ies against C2 (α6) proteasomal subunit as loading protein control for
quantiﬁcation [3]. To study the effect of H2O2 treatment on total protein
degradation, cells 48 h after transfection were starved in medium
lacking methionine and cysteine for 1 h and metabolically labeled
with 200 μCi/ml of [35S] methionine/cysteine (GE Healthcare) for 1 h
(pulse) in medium lacking methionine/cysteine. After the pulse, cells
werewashed three timeswith cold PBS and either untreated or exposed
to H2O2 as described above. After treatment, cells were cultured (chase)
in complete medium containing an excess of cold methionine (1 mM)
and cysteine (5 mM). For themeasurement of total protein degradation
of metabolically labeled proteins, an aliquot of cells and medium was
lysed in SDS sample buffer and total proteins were precipitated with
20% trichloroacetic acid. Total radioactivity was determined in an
aliquot of the supernatant after TCA precipitation and of the protein
pellets (pellets were washed three times with a mixture 50:50 of
acetone/ethanol in the cold, before solubilization in 0.1 N NaOH) by
liquid scintillation counting (Beckman LS 5000CE). The percentage of
protein degradation was calculated as total cpm at the corresponding
time/total cpm at time 0 multiplied by 100, after background
subtraction. Pulse-chase experiments for Snca half-life determination
were also performed as described above. Cells transfected with Snca
and either or not co-transfected with hMsrA and B were starved for
Met during 30 min and pulse-labeled with [35S] methionine/cysteine
for 30 min and untreated or treated with H202. After the treatments
the cells were chased with complete medium and collected at the
times indicated. Cells were lysed in 50 mM Tris–Cl pH 7.5, 150 mM
NaCl, 0.5% NP40 and a cocktail of protease inhibitors (Sigma) was
centrifuged at 15,000 ×g for 20 min at 4 °C. The supernatants were
incubated by rocking for 1 h at 4 °C with protein G-Sepharose
(GE healthcare), clariﬁed by centrifugation as above and the
supernatants incubated overnight at 4 °C with anti-Snca monoclonal
antibodies. Next day, protein G-Sepharose beads were added and
incubation was continued with rocking at 4 °C for 4 h. Beads were
washed three times with the buffer indicated above and proteins
were eluted with SDS-LB and loaded onto 15% SDS-PAGE. Gels were
stainedwith Coomassie, destained, dried and exposed in an appropriate
cassette with a phosphor screen. Imaging and quantiﬁcation was
performed with a Typhoon scanner (GE Healthcare).
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3.1. Mapping proteasomal subunits that interact with Snca
To identify the possible subunits of the proteasome implicated in the
recognition and degradation of Snca, biotinylated wild type Snca was
used. Biotinylated Snca was detected by developing Western blots
with streptavidin-alkaline phosphatase (Fig. 1A). The biotinylated
Snca was an effective substrate for the 20S proteasome as shown in
Fig. 1B, and was degraded as efﬁciently as the unlabeled Snca. Biotinyl-
ated Sncawas then used in a “FarWestern” analysis against 20S protea-
some and binding to a 28–29 kDa proteasomal subunitwas detected. To
identify the proteasomal subunit(s) that directly interacts with Snca,
puriﬁed proteasome, several recombinant proteasomal subunits and
GST as control were used for “Far-Western” analysis. As shown in
Fig. 1C, biotinylated Sncawas found to bind to a 28–29 kDa proteasomal
subunit as mentioned above and to the puriﬁed C8 (α7) proteasomal
subunit, but not to proteasomal subunits C9 (α3), C2 (α6) or GST
(Fig. 1C). Several constructs of the C8 (α7) subunit were then used to
map the regions implicated in the recognition of Snca. The results
obtained by “Far-Western” blots of different deletion constructs of C8
(α7) proteasomal subunit indicated that the COOH terminal region of
the C8 subunitmight be implicated. As a consequence,wemade a fusion
construct of GST and the C-terminal region of the C8 (α7) subunit,
GST-C8Ct, GST fused to the COOH-terminal of the C8 (α7) subunit
comprising amino acids 190 to 255. Pull-down assays were performed
and the GST-C8Ct protein construct, but not GST, effectively pulled
down Snca (Fig. 1D and E). Accordingly, the protein construct
GST-C8Ct could be predicted to compete with the proteasome for
binding to Snca preventing Snca degradation by the proteasome. The
GST-C8Ct construct was not degraded by the 20S proteasome and
effectively, as shown in Fig. 1F, it produced a dose-dependent inhibitionFig. 1. Proteasomal subunits interacting with alpha-synuclein for degradation. A, shows a repre
developed with streptavidin labeled with alkaline phosphatase. B, shows a representative blot
(69 nM), C60 is a control reaction for 60 min in the presence of 10 μM Lactacystin. C, shows
analysiswith biotinylated Snca developedwith streptavidin-alkaline phosphatase, the proteins
GST and 20S proteasome complex. D, shows a Coomassie blue stained gel of the indicated p
experiments. E, shows a Coomassie blue stained gel of pull-down assays using GST or GST-C8C
in the pull down assay where GST-C8Ct was used. F, shows representative Coomassie blue stain
(69 nM) for 30 min in the absence (lane 0) or in the presence of increasing amounts of GST-Cof the degradation of Snca by the 20S proteasome, while GST has no
effect. These results clearly indicate that degradation of Snca by the
proteasome is due, at least in part, to the binding of Snca to the C8
(α7) subunit of the proteasome.3.2. Mapping Snca regions implicated in proteasomal degradation
Snca can be cleaved endoproteolytically by the proteasome as
demonstrated by the use of double capped (N- and C-terminus) and
circularized Sncamolecules [30], but those experiments did not identify
the Snca protein region involved in recognition by the proteasome. To
identify the possible regions of Snca recognized by the proteasome,
we made four GST-Snca fusion constructs comprising amino acids:
1–140 (full length), 1–60, 1–95 and 61–140. Degradation of those
constructs by the 20S proteasome is presented in Fig. 2A and B. The
results obtained revealed that GST Snca 1–140, 1–60 and 1–95
(Fig. 2A and B) were degraded by the 20S proteasome, although with
slower kinetics than the His-tagged Snca (see below, Fig. 2C). In
contrast, GST and GST Snca 61–140 were not signiﬁcantly degraded
(Fig. 2A and B). Note that only the Snca moiety of the fusion protein
was degraded by the 20S proteasome, as an accumulation of GST
was observed during the time course of the degradation reactions.
Accordingly, we made His-tag versions of full length Snca, Snca 1–60
and Snca 61–140 and tested their degradation by the 20S proteasome.
Results presented in Fig. 2C showed that both His-tag full length and
1–60 Snca proteins were efﬁciently degraded by the 20S proteasome,
while Snca 61–140 was not signiﬁcantly degraded. Furthermore, the
untagged Snca 1–109 lacking the C-terminal acidic region is also
efﬁciently degraded by the 20S proteasome (Fig. 2D). Taken together,
all the results suggested that degradation of Snca by the proteasome
could be explained, at least in part, by the interaction of the N-terminalsentative blot of the detection of different amounts of biotinylated alpha-synuclein (Snca)
of a time course of the degradation of biotinylated Snca (1 μg, 3.5 μM) by 20S proteasome
representative blots stained with Ponceau red and the corresponding “Far Western” blot
loaded are recombinant proteasomal subunits:C2 (α6), C8 (α7) and C9 (α3), recombinant
uriﬁed recombinant proteins GST, GST-C8 C terminal (190 to 255) used for pull-down
t bound to glutathione-Sepharose in the presence of Snca. Note that Snca is only present
ed gel of the degradation of 3,5 μM Snca (lane C, control 1 μg, 3,5 μM) by 20S proteasome
8Ct (0.3–1.2 μM) and GST (0.38–1.5 μM), as indicated.
Fig. 2. Determination of the region of alpha-synuclein responsible for proteasomal degradation. Degradation reactions of the different alpha-synuclein (Snca) protein constructs were
performed in the presence of 20S proteasome (69 nM). A and B, GST and different GST-Snca constructs were incubated with 20S proteasome for the times indicated, reaction products
were analyzed by immunoblotting with anti-GST and anti-Snca antibodies, as indicated. Lanes labeled Lacta are similar incubations for the longest time indicated (2 h for panels
shown under A, and 3 h for B panels) in the presence of 10 μM Lactacystin. C, Coomassie blue stained gels of time course of degradation of His-tag Snca (full length), Snca 1–60 and
61–140 constructs, as indicated. D, Coomassie blue stained gels of time course of degradation of untagged Sncawt and Snca stop 109. Control reactions in the presence of 10 μM lactacystin
for panels C and D showed also complete inhibition of the degradation.
Table 1
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proteasome.Summary of peptide released from native wild type Snca by degradation with 20S
proteasome.
Peptide start-end Observed mass H+ HPLC peak number
(see Supplementary Fig. 1)
Peptide size
1–11 1226.80 Peak 7 11
1–13 1483.82 Peak 5 13
1–14 1540.85 Peak 5 14
1–17 1810.20 Peak 9* 17
1–18 1881.26 Peak 9* 18
1–24 2566.56 Peak 12 24
1–25 2623.53 Peak 12 25
1–25 2623.59 Peak 13 25
1–27 2793.74 Peak 14 27
1–28 2922.81 Peak 14 28
18–40 2348.73 Peak 2 23
18–50 3370.92 Peak 1 33
19–40 2277.66 Peak 2* 22
35–55 2129.21 Peak 5 21
37–55 1943.46 Peak 2* 19
51–77 2585.52 Peak 11 27
56–83 2814.76 Peak 12* 28
78–98 2049.47 Peak 2* 21
83–100 1763.16 Peak 7 18
84–110 2673.86 Peak 2* 27
85–110 2616.37 Peak 1 26
85–112 2786.50 Peak 5 28
111- GILEDMPVDP Peak 1
120–140 2462.97 Peak 1* 21
120–140 2478.98 Peak 1 21
Average peptide
size ± S.D.
22.3 ± 5.6
All peptides were sequenced by MALDI-TOF MS/MS. The observed peptide mass differs
from the calculated mass for the corresponding peptide ± 0.2 Da. Those peptides
labeled with an asterisk have also been identiﬁed by Edman N-terminal sequencing of
the corresponding HPLC fraction. The unique peptide without a mass value was only
identiﬁed by Edman N-terminal degradation.3.3. Peptide analysis of Snca cleavage by the proteasome
To determine the sites of cleavage of Snca by the proteasome,
degradation reactions were analyzed by reverse-phase HPLC and the
separated peptides subjected to identiﬁcation and sequencing by
Edman degradation and mass spectrometry. A representative reverse
phase HPLC proﬁle of peptides generated by proteasome digestion of
wild type Snca is presented in Supplementary Fig. 1. Note that the
height of all eluted peaks increased with incubation time. Parallel
reactions analyzed by SDS-PAGE showed that less than 10% of the
total Snca present in the reaction mixture was degraded after 30 min.
Eluted peptides were identiﬁed by a combination of N-terminal
Edman degradation and directMALDI-TOFMS/MS. The results obtained
are summarized in Table 1, the average length of the peptides released
by proteasomal digestion was 22.3 ± 5.6 amino acids. The fact that
less than 10% of the total input of Snca was degraded under these
conditions, those data likely represent primary cleavage sites in the
Snca molecule by the proteasome. Table 2 summarizes peptides
where both N- and C-terminal contiguous peptides have been
identiﬁed. A graphical representation of the digestion map of Snca by
the 20S proteasome is presented in Fig. 3. The longest peptides
(Table 3) were used to draw the upper line (green line) in Fig. 3. Black
bars (below the green line in Fig. 3) represent all peptides whose
sequences were determined (taken from Table 1). Starting at the
N-terminal methionine we obtained a peptide extending from 1 to 17
and the contiguous peptide from 18 to 50. In the C-terminal region we
observed a prominent peptide 120–140, and cleavage at position 110
(P1) with the longest peptide observed spanning from position 63 to
110. The peptide spanning from 111 to 119 was not detected by
Table 2
Sequence around cleavage sites of native Snca wild type by the proteasome where
both N- and C-terminal derived peptides have been identiﬁed.
Start N-terminal C-terminal End
10 KAKEGVVA ↓ AAEKTKQG 25
27 AEAAGKTK ↓ EGVLYVGS 42
29 AAGKTKEG ↓ VLYVGSKT 44
33 TKEGVLYV ↓ GSKTKEGV 48
43 KTKEGVVH ↓ GVATVAEK 58
48 VVHGVATV ↓ AEKTKEQV 63
70 VVTGVTAV ↓ AQKTVEGA 85
103 NEEGAPQE ↓ GILEDMPV 118
112 ILEDMPVD ↓ PDNEAYEM 127
P1 sites are denoted with bold characters.
Table 3
Longest contiguous peptides released by 20S proteasome degradation of wild type Snca.
Start N-terminal End C-terminal
1 MDVFMKGLSKAKEGVVA 17 ↓ AAEKT
18 AAEKTKQGVAEAAGK… 50 ↓ GVATV
51 GVATVAEKTKEQVT… 77 ↓ AQKTV
84 GAGSIAAATGFVKKD… 110 ↓ GILED
111 GILEDMPVD 119 ↓ PDNEA
120 PDNEAYEMPSPD… 140
Data from this table are represented by a green line in Fig. 3.
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Edman degradation.3.4. P1 cleavage sites of proteasomal degradation of Snca and analysis of
ﬂanking residues
Analysis of the proteasomal P1 cleavage sites where both N- and
C-terminal peptides have been identiﬁed (Table 2) showed thatFig. 3. Graphical representation of the digestion map generated from degradation of alpha-s
synuclein (Snca) is presented; a schematic representation of the 7 repeats of the Snca N-term
amino acid; red, acidic amino acid; gray, aliphatic amino acid, green, Thr. Black bars on the
(Table 1), the light green line indicates a peptide identiﬁed by N-terminal Edman degradation
Snca sequence; the P1 position for each released peptide is highlighted in orange. Note that
shows WebLogo representation of amino acid preference surrounding the identiﬁed P1 clea
sites compared with the total 11-mer possible peptides where no cleavage sites was found. Th
different positions with respect to P1and the level of signiﬁcance are also indicated for a bin
shows a WebLogo representation of the consensus sequence of the N-terminal repeats of Snc
cleavage site on the N-terminal region of Snca.preferential cleavages have taken place after hydrophobic amino acids
(V and A, four peptides), after acidic amino acids (E and D, two
peptides) and one cleavage site after K, G and H, respectively. When
all peptides released by proteasomal digestion of Snca (Table 1) were
considered and using WebLogo [15], a representation of the consensus
cleavage sequence around P1 sites was generated (see Fig. 4B). The
clustering of repetitive elements in the N-terminal region of Snca and
the abundance of identiﬁed peptides from this region indicated
dominant cleavages at P1 after an aliphatic amino acid of the repetition
followed by a small amino acid like G (cleavage after A or V at P1,
followed by G at P′1). Due to the clustering of acidic residues of Snca
in the C-terminal region, the preferred sites of cleavage by the
proteasome in that region were after acidic amino acids (D. E). Clearlyynuclein wild type by 20S proteasomes. A, the complete amino acid sequence of alpha-
inal region is shown below the amino acid sequence. Color code is as follows: blue, basic
upper part of the protein sequence are the peptide released by proteasomal digestion
(see also Table 1). Upper green line represents contiguous peptides that cover the entire
region 78 to 83 is in gray color because the corresponding peptide was not identiﬁed. B,
vage sites. C, D and E are two sample Logos of the amino acids surrounding P1 cleavage
e preferred amino acids (enriched) at the indicated locations or disfavored (depleted) at
omial distribution (note that A with * denotes: aliphatic amino acid; Ala, Val or Leu). F,
a (two repeats in tandem are shown) and below the consensus sequence of proteasomal
Fig. 4. Degradation of aggregated alpha-synucleins by 20S proteasome. Coomassie blue stained gels of time course of the degradation of native and aggregated (for 5 days, 12 days or
1 month) alpha-synucleins (Snca) wild type and the missense mutants by 20S proteasomes. Total Snca at time 0 corresponds to 7 μMmonomeric Snca for both native and aggregated
Sncas, reactions performed in the presence of 173 nM 20S proteasome. Graphs show the corresponding quantiﬁcations as means ± s.e.m. from three different experiments.
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get an indication of a possible preferential sequence surrounding the P1
cleavage sites of Snca, we used the two sample Logos [56]. The “positive
sample” for the analysis was the collection of 11-mer peptides centered
at the P1 position of actual cleavage sites of Snca and the “negative
sample” was the collection of all possible 11-mer peptides that can be
generated from the entire Snca sequence, excluding those peptides
that were present in the positive sample. Using the binomial distribu-
tion for comparison, we obtained the graphical two sample Logos
presented in Fig. 4C, D and E at different signiﬁcant p values. Note that
in the analysis of two sample Logos, A stands for either A, V or L and E
stands for either D or E at P1 position. As expected with low stringency
(p b 0.1) the preferred cleavage site (P1 site, bold and italics) can be
described by the sequence: X G/KVKX hydrophobic (V, A, L)/acidic
(E, D) GXXTK (Fig. 4C). Increasing the stringency to p b 0.05 the
preferred sequence can be described by the sequence: XG/KXKX
(V, A, L) GXXTX (Fig. 4D), being both the P1 amino acid (V, A and L,
hydrophobic) and the P′4 amino acid consensus preserved at
p b 0.001 (Fig. 4E). As expected, the most stringent consensus
derived sequence clearly reﬂects the cleavage consensus of peptides
released from the N-terminal repetitive region of Snca. Accordingly,
it was interesting to align the cleavage preference of the proteasome
in the N-terminal region of Snca with the consensus sequence of the
N-terminal 11-mer repeats of Snca also obtained by using WebLogo
[15]. Direct ﬁt with one 11-mer repeat of Snca was not possible;
the best ﬁt was obtained with the consensus sequence of two repeats
in tandem, as shown in Fig. 4F. The proposed alignment allowed
matching of P1 cleavage site with amino acid 10 of the ﬁrst tandem
repeat and P′1 was amino acid 11 of the ﬁrst repeat of the tandem,
showing the preference for Gly at that location for cleavage.
Accordingly, P′4 (Thr) matched position 3 of the second tandem
repeat. The alignment was conﬁrmed by manual inspection of
peptides release by the 20S proteasomal digestion from the
N-terminal region of Snca. Direct visualization of the alignment can bechecked in Fig. 3; just compare the alignment of peptides generated
by proteasomal digestion with the color-coded scheme of the repeats
presented under Snca amino acid sequence.
Taken these data together with those shown above on the region
of Snca required for proteasomal degradation, it can be concluded
that the C-terminal portion of Snca from amino acids 110–140 is not
essential for Snca degradation (Snca stop 109 is degraded as efﬁciently
as full length Snca). Furthermore, the initial cleavage of Snca by the
proteasome must be taking place within the N-terminus, but not by
direct N-terminus guided entrance to the proteasome catalytic
chamber, as the N-terminal His-tag version of Snca is also degraded by
the 20S proteasome.
3.5. Proteasomal degradation of aggregated Snca
Snca aggregation and ﬁbrillarization by a nucleation-dependent
process is a property of Snca shared with other amyloid proteins [14].
We wanted to study the degradation of those Snca aggregates by the
20S proteasome in vitro. Snca wild type and its mutants were aggregat-
ed by incubation at 37 °Cwith shaking for different periods of time. The
aggregation was monitored by ThT binding, electron microscopy and
Western immunoblot. At different times of aggregation, the degradation
of Snca by the proteasome was also studied. After incubation for
3–5 days at 37 °C, all four types of Snca reached a plateau in ThT
ﬂuorescence. Those samples (3–5 days of incubation) showed the
presence of aggregates and ﬁbril structures, as illustrated by the images
obtained by electron microscopy of the negatively stained preparations
of aggregated Snca as shown in Supplementary Fig. 2. Those images did
not change signiﬁcantly thereafter with longer incubation periods
(12 days or even after 1 month). Degradation of aggregated Sncas by
the proteasome was then studied. Aggregation of all four Snca variants
produced a signiﬁcant decrease in the degradation rate of the
monomeric Snca, still present in the aggregated samples, by the
proteasome, becoming almost completely resistant to degradation
Fig. 5.Analysis of degradation by the proteasome of aggregated alpha-synucleins by immunoblot and silver staining. Alpha-synuclein (Snca)wild typewas aggregated for 5 (A) and 12 (B)
days and subjected to degradation by 20S proteasomes. Total Snca at time 0 corresponds to 3.5 μMmonomeric synuclein and the reactions were performed in the presence of 69 nM 20S
proteasome and developed by immunoblotwith our own anti-Snca polyclonal antibodies. Lower panels show the region ofmonomeric Sncawith shorter exposure to better appreciate the
degradation of monomeric Snca. Lane labeled Lacta is a similar reaction mixture incubated for 90 min in the presence of 10 μM Lactacystin. C, Silver stained gel of the analysis of
degradation reactions by the proteasome of the different Snca variants aggregated for 12 days and assayed under similar conditions to those described above.
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of the other species of Snca that are formed during the in vitro process of
aggregation,we analyzed the degradation reactions by immunoblotting
and silver-staining. After 5 days of aggregation, the main SDS-resistant
Snca speciesmigrated as a possible dimer, andwas degraded by the 20S
proteasome with a rate similar to the monomeric Snca (Fig. 5A). After
12 days of aggregation, the amounts of SDS-resistant, high molecular
weight Snca species were increased (Fig. 5B) and those species were
fully resistant to degradation by the 20S proteasome. The monomeric
Snca still present in those preparationswas degradedwhile at a reduced
rate, as already shown in Fig. 4. The immunoblot technique is very
sensitive, but it could be that some of the Snca aggregated species
were not detected. Accordingly, we performed similar experiments to
those shown above, but processing the protein gels for silver staining,
and a representative experiment is presented in Fig. 5C. The analysis
of these results indicated that the 20S proteasome was able to degrade
the monomeric Snca still present in the sample of 12-day aggregated
Snca (more slowly than native Snca), while the higher molecular
weight species were not signiﬁcantly degraded, conﬁrming the results
obtained by Western immunoblotting (Fig. 5B).
3.6. Snca oxidation and degradation by the proteasome
The results obtained with aggregated Snca pointed out that some
modiﬁcation of the protein occurred during the prolonged time ofincubation at 37 °C preventing the degradation by the proteasome.
Therefore, samples of wild type native Snca and Snca that was aggregat-
ed for 5 days were analyzed by ESI-MS. The data showed the presence
of monomeric Snca molecules in the aggregated samples with higher
molecular mass than the native Snca 14460 vs 14524, the +64 Da
mass increase could be attributed to the oxidation of the four Met of
Snca, similar results were obtained with samples aggregated for
12 days. These results suggested that the main modiﬁcation of
monomeric Snca during the aggregation process could be Met
oxidation. Accordingly two predictions could be made, 1) if oxidation
was prevented during the course of the incubation for aggregation,
the inhibition of the degradation of aggregated Snca should be
overcome and 2) oxidation of native Snca should prevent its
degradation by the proteasome. As shown in Supplementary Fig. 3,
inclusion of 10 mM 2-mercaptoethanol during the course of the
aggregation process fully restores the rate of degradation of the
monomeric Snca. To test the second prediction, Snca wild type was
oxidized with either H2O2, chloramine T (ChT) or Fe and ascorbic acid.
To judge the nature and extent of Snca modiﬁcation, we derivatized
the possible protein carbonyls with 2,4-dinitrophenylhydrazine
(DNPH) and detection with anti-DNP antibodies. As shown in Fig. 6A
mild oxidation with H2O2 did not produce signiﬁcant carbonylation of
Snca. In contrast, more drastic oxidation conditions (ChT and ferric
ions plus ascorbate) produced high levels of carbonylation as shown
by reaction with anti-DNP antibodies (Fig. 6A). When degradation
Fig. 6. Oxidative modiﬁcation of alpha-synuclein inhibits its degradation by the proteasome. A, Immunoblot analysis with anti-DNP antibodies of wild type synuclein (Snca) untreated
(C, control) or treated under different oxidative conditions (as indicated) and subjected (or not) to prior derivatization with DNPH, lower panels show immunoblot of the same samples
in a different gel and probed with anti-Snca antibodies. B, shows Coomassie blue stained gels of the time course of degradation of Snca wild type untreated or treated with the indicated
oxidative agents prior to assay its degradation by 20S proteasomes. Graph shows the corresponding quantiﬁcations as means ± s.e.m. from three different experiments. C, shows
Coomassie blue stained gels of the time courses of degradation of Snca wild type and the missense mutants untreated or treated with H2O2 prior to perform their degradation by
proteasomes. Graph shows the corresponding quantiﬁcations as means ± s.e.m. from three different experiments. Degradation reactions were performed at substrate concentration of
7 μM in the presence of 69 nM 20S proteasome.
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we observed that mild oxidation with H2O2 of Snca had a signiﬁcant
inhibitory effect on its degradation by the proteasome (Fig. 6B).
Furthermore, the highly carbonylated Snca was not signiﬁcantly
degraded by the proteasome (Fig. 6B). H2O2 treatment of the other
Snca variants also inhibited their degradation by the proteasome
(Fig. 6C). Taken together, these results showed that Met oxidation was
likely responsible of the inhibition of degradation of monomeric Snca
still present in the aggregated Snca preparations and that oxidation of
native Snca prevented its degradation by the proteasome.
3.7. Mapping Snca oxidized methionines and repair by methionine
sulfoxide reductases
There are 4 Met residues in Snca M1, M5, M116 and M121. To test
which Met could be implicated in the inhibitory effect produced by
Met oxidation, we used the protein constructs Snca stop109 that lacks
the C-terminal methionines and His-tag Snca 1–60 that only contains
the two N-terminal Met residues. Those Snca protein constructs were
subjected to oxidation with H2O2 and their degradation by the
proteasome was studied. As shown in Fig. 7A and B, both Snca stop
109 and Snca 1–60 degradation were inhibited by pretreatment of the
proteins with H2O2. These results suggested that the Met residues
which when oxidized inhibited Snca degradation by the proteasome
were likely located at the N-terminal part of Snca (Met 1 and 5). If
this preliminary conclusion was correct, oxidation of Snca protein
constructs where those Met residues are substituted by Ala, preventing
oxidation, should be degraded with rates similar to wild typeirrespective of their treatment with H2O2. As shown again in Fig. 7C,
degradation of oxidized wild-type Snca was slower than degradation
of native Snca. The mutation M5A, by itself, did not affect signiﬁcantly
the rate of degradation compared to wild-type Snca (Fig. 7C). In
contrast, oxidized M5A Snca has a reduced rate of degradation, but its
degradation rate was faster than the degradation of oxidized wild-
type Snca (Fig. 7C). To obtain the Met1Ala mutation, the ATG initiator
codon must be changed; as a consequence we introduced another
starting Met and then to remove the N-terminal His-tag peptide. All
the proteins used in these assays (Fig. 7C) were treated to remove
the His-tag N-terminal moiety as described under “Materials and
methods”. The double Met 1, 5 Ala Snca mutant was also degraded
with similar kinetics as the wild-type Snca (Fig. 7C). Noteworthy, the
Met 1, 5 Ala Snca mutant after H2O2 treatment had a similar rate of
degradation as the untreated Snca native protein (Fig. 7C). These results
indicated that both Met1 and Met5 at the N-terminus were critical for
the inhibition of degradation of the oxidized Snca by the proteasome.
Furthermore going back to the study of degradation of aggregated
Snca by the proteasome, the aggregated Met 1, 5 Ala Snca have a rate
of degradation similar to the native Met 1, 5 Ala (Supplementary
Fig. 5), while the SDS-resistant species generated (high molecular
weight) were not degraded. These results reinforce the conclusion
that Met 1, 5 oxidation is the main cause of the observed inhibition of
degradation of the aggregated Sncawith prolonged times of incubation.
Methionine sulfoxide (MetO) modiﬁcations of proteins can be re-
versed by the methionine sulfoxide reductases [50]. As a consequence,
we decided to explore the possible reversion of SncaMetO by treatment
with puriﬁed human recombinant MsrA and B (hMsrA plus hMsrB).
Fig. 7. Analysis of Met residues implicated in the inhibition of degradation of oxidized alpha-synuclein. A and B, show Coomassie blue stained gels of time courses of degradation of
synuclein (Snca) stop 109 (A) and His-tag Snca 1–60 (B) untreated or treated with H2O2. Graphs show the corresponding quantiﬁcations as means ± s.e.m. from three different
experiments. C, shows Coomassie blue stained gels of the time courses of degradation of full length Snca wild type and Snca mutants Met5Ala and Met 1, 5 Ala untreated or treated
with H2O2 prior to proteasomal degradation. Graph shows the corresponding quantiﬁcations as means ± s.e.m. from three different experiments.
Fig. 8. Inhibition of degradation of oxidized alpha-synuclein is reverted by treatment with
methionine sulfoxide reductases. The panels show Coomassie blue stained gels of the time
courses of degradation of alpha-synuclein (Snca) wild type untreated or oxidized by
treatment with H2O2. Native or oxidized Snca were afterwards incubated with
recombinant hMsrA and B with or without DTT as indicated in the ﬁgure with plus and
minus signs. Graph shows the corresponding quantiﬁcations as means ± s.e.m. from
three different experiments.
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RedOx donor did not change its rate of degradation by the proteasome
(Fig. 8). DTT treatment had also no effect on the rate of degradation of
oxidized Snca by the proteasome (Fig. 8). In contrast, the treatment of
oxidized Snca with hMsrA plus hMsrB in the presence of DTT repaired
the damaged protein that was then degraded by the proteasome with
a rate similar to the native untreated Snca (Fig. 8). These results clearly
indicated that the oxidation of Met residues of Snca was reversible and
as a consequence the repaired protein becomes undistinguishable from
the native Snca as a substrate for proteasomal degradation.
3.8. Oxidative stress and Snca degradation in cells
The data presented above clearly illustrated a RedOx mechanism
that in vitro regulated Snca degradation by the proteasome, the obvious
question was its relevance in a cellular context. To address this issue,
N2A cells were transfected with Snca alone or together with the
hMsrA plus hMsrB, and either untreated or treated with H2O2. The
degradation of Snca was followed after treatment of cells with CHX by
immunoblot analysis and the data obtained are presented in Fig. 9A.
Snca degradation was slightly activated by co-transfection with hMsrA
plus hMsrB (Fig. 9A). The degradation of Snca was strongly inhibited
by treatment of cells with H2O2 and this effect of H2O2 was completely
reverted by co-expression of hMsrA plus hMsrB. To qualify these results,
we studied the effect of H2O2 on total protein degradation by pulse-
chase experiments of Snca transfected cells. Treatment of cells with
H2O2 produce an increase of total protein degradation both, short-
term (2 h) and long term (24 h) degradation. These results are in
agreementwith previous results that oxidative stress causes an increase
in protein degradation rate mainly by the proteasomal pathway [23].
Fig. 9. Inhibition of degradation alpha-synuclein by treatment of cells with H2O2 is
reverted by co-transfection with methionine sulfoxide reductases. N2A cells were
transiently transfected with wild type alpha-synuclein (Snca) cDNA with empty vector
(pcDNA) or with hMsrA plus B pcDNA constructs. After transfection cells were either
treated or untreated with H2O2, and CHX; in the presence or in the absence of 10 μM
Lactacystin (Lacta). Upper panel showsWestern immunoblot analysis of total cell extracts
with anti-Snca monoclonal antibody, and proteasomal C2 (α6) used as loading control.
Graph shows the corresponding quantiﬁcations as means ± s.e.m. from three different
experiments.
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with 35SMet/Cys of N2A cells transfected with Snca under control
conditions and after treatment of the cells with H2O2 in the absence or
in the presence of co-transfected hMsrA plus hMsrB. Similar to CHX ex-
periments, H2O2 treatment produced a slowdown of Snca degradation
that was reverted by cotransfection of hMsrA and B. As a consequence,
the effect of H2O2 causing inhibition of the degradation of Snca seems
to be speciﬁc, as total protein degradation by the proteasome was
stimulated by treatment of cells with H2O2.
4. Discussion
The results presented here allow us to draw some conclusions about
the molecular mechanism of degradation of Snca by the proteasome.
The primary interactions of Snca with the proteasome occur by binding
of the N-terminal region of Snca (1–60) with the C-terminal region of
proteasomal C8 (α7) subunit. MS analysis of Snca released peptides
has known limitations, not all released peptides can be identiﬁed nor
can their absolute abundance be estimated. Nevertheless, since almost
the entire Snca protein sequence was covered by the MS peptide data,
one can assume that at least the results obtained are a representative
subset of the total peptides present in the degradation mixture under
analysis. Snca 1–60 is readily degraded by the proteasome, suggestingthat the initial endoproteolytic cleavage is taken place within the
N-terminal region of Snca. From MS data, one of those sites must have
its P1 position of cleavage between amino acids 11 and 28 (Table 1
and Fig. 3) and another main cleavage site must be located between
amino acids 35 and 55 (Tables 1, 2 and Fig. 3). In fact, within the 1–60
region of Snca we have identiﬁed contiguous peptides ranging from 1
to 17 and from 18 to 50. After this initial proteolytic attack the rest of
the Snca molecule is degraded by cleavages generating peptides
with P1 positions at 77 and 83 (while the expected peptide 78–83
was not detected) and cleavage at P1 positions 110 and 119 within
the C-terminal portion of Snca.
The detailed analysis of cleavage sites within the N-terminal repeats
of Snca showed that cleavages are taking place mainly after hydropho-
bic amino acids, while the cleavage sites within the C-terminal region
are taking place mainly after acidic residues (Table 3 and Fig. 3). The
proteasome catalytic subunits involved in those cleavages could be β5
(chymiotrypsin-like activity) andβ1 (post-glutamic hydrolase activity),
respectively. The “consensus” sequence for the region surrounding the
P1 sites of Snca cleavage differs (Fig. 3) from those reported in the
study of enolase degradation by wild type yeast proteasome or β5, β1
singlemutants [37]. Using the PraPoc algorithmof proteasome cleavage
sites [38] with Snca and wild type yeast proteasome, the program
predicted 41 potential P1 sites (with different probabilities, scored
from + to +++), missing 12 out of the 21 different P1 identiﬁed by
MS sequence analysis. The program prediction correctly identiﬁed 9 of
the experimentally determined P1 sites, mainly corresponding to
those sites located at the N-terminal region of Snca (the algorithm
predictions did not improve using the erythrocyte proteasome trained
with enolase). Probably the speciﬁc characteristics of Snca primary
sequence, clustering of repetitions at the N-terminus and clustering of
acidic amino acids at the C-terminus, may explain the apparent bias
from the already relaxed speciﬁcity of the different active β subunits
of the proteasome [37].
Snca in solution has been determined to have a hydrodynamic
radius of 28.2 Å increasing to 36.4 Å in the presence of 8 M urea, the
predicted value for a total random coil would be a hydrodynamic radius
of 36.9 Å [41]. The more compact structure of wild type Snca and their
variants in solution than the one expected for a random-coil conforma-
tion is likely due to the interaction of the positively charged N-terminus
with the acidic C-terminus [45]. Accordingly, Snca with an estimated
diameter of 56.4 Å is unlikely to enter the narrow passage of the
α-ring annulus estimated to be 13 Å in diameter [12]. More likely Snca
could open the “gate” formed by the N-terminus of the α-subunits,
followed by its unfolding and penetration into the α-antechambers, as
suggested by Liu et al. [30]. How Snca promotes its own gating into the
proteasome? We cannot provide an experimentally-derived answer to
this question.More sophisticated techniques out of our reach are needed
[46]. A plausible explanation is suggested by the experiments showing
that Snca interacts with the C-terminus of C8 (α7) subunit, but other
important interactions cannot be discarded. Based on yeast proteasome
structure [22], the C-terminus of the α7 subunit (not completely
resolved in the crystal) should likely point out of the proteasomal
cylinder, Snca gating could be due to the binding of Snca to the
C-terminal region of C8 (α7) subunit promoting a conformational
change that would be transmitted to the N-terminus of the C8 (α7)
subunit that may help opening the gate formed by the interactions of
the N-terminus of subunits α1, α2, α3, α6 and α7 that hinder the
passage through the α-ring annulus. Another possibility could be that
the Snca C-terminus, while not required for Snca degradation by the
proteasome, may behave as “gate opener”, and this possibility has
been discarded experimentally as neither GST 61–140 nor His tag
Snca 61–140 has any effect on the degradation of full length Snca.
Therefore, gating and translocation seems to reside in the N-terminal
part (1–60) of the Snca molecule. The endoproteolytic cleavage of
Snca in the catalytic chambers will require docking of a Snca molecule
on a Thr-1 of an active subunit promoting the catalytic cleavage at
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peptides released that correspond to the N-terminal region of the
Snca molecule; residues 35 to 55 may play such a role in this initial
anchoring, promoting an initial cleavage at positions 11 to 28, and in
particular generating the contiguous Snca peptides 1–17 and 18–50.
The fact that Snca is able to form aggregated and ﬁbrillar structures
in vitro makes interesting to study its degradation. Under in vitro
conditions, most of the ﬁbrils formed are completely disrupted by
SDS-treatment generating monomeric Snca when analyzed by
SDS-PAGE; some modiﬁcations take place during prolonged incuba-
tions including the formation of high molecular weight species that
are resistant to SDS (Fig. 5), likely due to intermolecular cross-links
[20]. Those higher molecular species seem to undergo an “irreversible
process” becoming fully resistant to degradation by the proteasome
(Fig. 5A andB). The complete inhibition ofmonomeric Snca degradation
with prolonged times of aggregation could not be attributed only
to ﬁber formation, as ﬁbril formation attained its maximum after
3–5 days of incubation, as judged by ThT ﬂuorescence and electron
microscopy. These results made us to suspect that a modiﬁcation of
the primary structure of Snca was taking place and we tentatively
identiﬁed oxidation ofMet residues as amodiﬁcation that could explain
the inhibition of degradation. In fact, inclusion of 2-mercaptoehanol
during the aggregation process prevented the inhibition of monomeric
Snca degradation. Furthermore, direct oxidation of Snca wild type
and its missense mutants with H2O2 resulted in the inhibition of
proteasomal degradation and the critical residues responsible for this
inhibition were mapped to Met1 and 5 at the N-terminal portion of
Snca. Mutation of those Met residues to Ala prevented the observed
inhibitory effects of aggregation on its degradation, Snca Met oxidation
has also other consequences, oxidation of Snca with H2O2 prevents
its ﬁbrillarization and Snca MetO inhibits the ﬁbrillarization of native
un-modiﬁed Snca in vitro [54,24]. While Met 1 and 5 are the key Met
residues for Snca proteasomal degradation, oxidation of individual me-
thionines (tested by the use ofMet/Leu amino acid substitutions) seems
to contribute similarly to slow down the kinetics of ﬁbrillarization with
no signiﬁcant sequence-speciﬁc effect [24]. Within this context, Cu
binding to Snca and metal catalyzed Snca oxidation by Cu requires
and occurs at the N-terminal region of Snca, Met1 and less importantly
His50 [8,44] are required for Cu binding and Cu catalyzed oxidation
occurs at Met1 and 5 [27]. While Cu binding favors Snca ﬁbrillarization
[55], Cu mediated oxidation should prevent ﬁbrillarization of Snca.
Oxidative modiﬁcation of proteins is a major consequence of cell
oxidative stress and is widely accepted as a major factor implicated in
aging and neurodegenerative diseases, including PD [50,52]. Side-
chain amino acid modiﬁcation is the main result of protein oxidative
damage, being irreversible carbonylation of Lys and Arg residues the
most abundant and easily detected protein modiﬁcation [50]. As
shown here, Snca carbonylation completely abolishes its degradation
by the proteasome (Fig. 6, treatments with ChT and Fe plus ascorbic).
Carbonylated Snca wild type has been shown to be taken up and
degraded in vitro by lysosomes through chaperon mediated autophagy
(CMA) with slightly less efﬁciency than native Snca [34]. As a
consequence, it would be expected that carbonylated Snca, likely to be
accumulated during aging and oxidative stress [33], could only be
efﬁciently cleared in the cell by lysosomal degradation through the
CMA pathway. Another consequence of mild oxidative stress is the
oxidation of SH groups of Met (MetO) and Cys. MetO modiﬁcation is
reversible by the action of Msr enzymes. Msr enzymes are coupled to
a regenerating system formed by Trx, Trxr, and NADPH [50]. The
regenerating system also participates in the reversion of Cys disulﬁde
bridges and cysteine sulfenic acid [50]. Here we have shown that repair
of Snca MetO by treatment with MsrA plus MsrB restores the rate of
degradation of Snca by the proteasome. There is in the literature an
example of a protein whose oxidation has the opposite effect,
Calmodulin (CaM). CaM, like Snca, has no Cys. MetO oxidation of CaM
with H2O2 promotes its degradation by the 20S proteasome [18] andthe oxidation of N-terminal Met 51, 71 and 72 seems to be critical for
unfolding of CaM and proteasomal degradation [5]. The opposite effects
of oxidation on the degradation of Snca andCaMare againmanifested in
the reversion of MetO by Msr enzymes, leading to the recovery of the
degradation in the case of Snca (Fig. 8) and causing inhibition of CaM
[18]. Due to the relevance of Msr proteins in protein degradation, we
have also studied the possible association of proteasomes with Msr
proteins by co-immunoprecipitation analysis, but we failed to detect
any signiﬁcant association. In contrast, we were able to reproduce the
recently published association of a Trx-like protein Txnl1/TRP32 with
the 26S proteasome [2,62]. Furthermore, using oxidized CaM we have
found that Txnl1/TRP32 can substitute Trx as intermediate coupling
enzyme between MsrA and Trxr towards the ﬁnal NADPH electron
donor. Taken together, these results suggest that the proteasome
complex may behave as “dual decision” complex depending on the
protein substrate, for some proteins the repair of MetO will lead to
prevent their degradation, like CaM, but for some other proteins, like
Snca, their repair would facilitate its degradation.
We have also shown that treatment of cells with H2O2 greatly
diminished the degradation rate of Snca, both by studying Snca
degradation after treatment of cells with CHX and by radioactive
pulse-chase experiments, and this effect can be suppressed by
co-expression of MsrA plus MsrB, while total protein degradation is
increased upon treatment with H2O2 (Fig. 9 and Supplementary
Figs. 5 and 6) in agreement with previous results [23]. The role of Msr
proteins in recovery and protection against protein oxidation is well
established [29]. Interestingly in relation with PD, MsrA−/− mice
exhibit lower locomotor activity with age due to a decrease of
dopamine levels [39], MsrA overexpression also seems to protect cells
from dopamine and rotenone insults [31]. Finally, MsrA prevents the
locomotor and circadian rhythm defects caused by ectopic expression
of human Snca in Drosophila [59] and a decrease in Snca clearance has
been described in MsrA null mutants of budding yeast [40]. These
evidences also link MetO reversion by Msr to protection against
oxidative stress implicated in subrogate models of dopaminergic
damage related to PD pathology.
The new mechanistic insights provided here into proteasome
degradation of oxidized proteins, not all oxidized proteins would have
an increased rate of degradation by the proteasome, together with the
regulation of expression of proteasome subunits by oxidative stress
mediated by Nrf1 and 2 [47] and the reported dissociation of 26S
proteasome into 19S and 20S complexes by cell oxidative stress
[43,58] make the proteasome complex a selective key regulator of cell
proteostasis (degradation pathway) during oxidative stress.
In this study we have presented a clear picture of the molecular
mechanism of degradation of Snca by the proteasome, establishing the
critical role of the N-terminal region of Snca for its degradation and
reporting that RedOx state of Met 1 and 5 of Snca is a reversible
regulatory mechanism of Snca degradation by the proteasome. These
results would indicate that keeping Met 1 and 5 of Snca in its reduced
state would be beneﬁcial; and their oxidation to MetO may promote
cell dysfunction and could contribute to the development of PD
pathology. The Met oxidation of Snca may represent an alert
oxidative-stress signal for cell proteostasis (reversible), prior to
more extensive irreversible modiﬁcations (carbonylation). Future
work will further clarify the connection of Msr function and Snca
degradation both under physiological (aging) and pathological
conditions, allowing further understanding of the pathology of PD and
other synucleinopathies.
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